Filip De Keyser
De Keyser, Filip
VIAF ID: 279903163 (Personal)
Permalink: http://viaf.org/viaf/279903163
Preferred Forms
- 100 1 _ ‡a De Keyser, Filip
-
- 100 0 _ ‡a Filip De Keyser
4xx's: Alternate Name Forms (5)
Works
Title | Sources |
---|---|
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. | |
Assessment of sensitivity to change of the European Scleroderma Study Group activity index. | |
Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. | |
Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation | |
The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies | |
CARD15 variants determine a disturbed early response of monocytes to adherent-invasive Escherichia coli strain LF82 in Crohn's disease | |
Chronically inflamed synovium from spondyloarthropathy and rheumatoid arthritis investigated by protein expression profiling followed by tandem mass spectrometry | |
Construction and psychometric properties of the Belgian Rheumatoid Arthritis Disability Assessment (BRADA) questionnaire: a new tool for the evaluation of activity limitations in patients with rheumatoid arthritis | |
Decrease of disease activity under ineffective therapy in DMARD-naive patients with early rheumatoid arthritis: role of antibody profiles and carriage of the HLA shared epitope in predicting decrease of disease activity. | |
Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. | |
Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays | |
Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. | |
Dynamic T cell receptor clonotype changes in synovial tissue of patients with early rheumatoid arthritis: effects of treatment with cyclosporin A (Neoral). | |
Effect of infliximab treatment on T cell cytokine responses in spondylarthropathy: comment on the article by Zou et al. | |
Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis | |
Erratum: Corrigendum: Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus | |
Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides | |
Fuchs' Uveitis Syndrome: No Longer a Syndrome? | |
Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. | |
The heart and pulmonary arterial hypertension in systemic sclerosis | |
Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study | |
The histopathology of spondyloarthropathy | |
Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay | |
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy | |
Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. | |
Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. | |
In pursuit of B-cell synovial autoantigens in rheumatoid arthritis: Confirmation of citrullinated fibrinogen, detection of vimentin, and introducing carbonic anhydrase as a possible new synovial autoantigen | |
Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy | |
Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. | |
Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation | |
The influence of ageing on the development and management of rheumatoid arthritis | |
The integration of the detection of systemic sclerosis-associated antibodies in a routine laboratory setting: comparison of different strategies | |
Localization of MHC class II/human cartilage glycoprotein-39 complexes in synovia of rheumatoid arthritis patients using complex-specific monoclonal antibodies | |
Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. | |
Management of inflammatory bowel disease in pregnancy | |
Mensen met artritis : het verschil tussen hebben en zijn | |
Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions | |
Nailfold capillaroscopy for prediction of novel future severe organ involvement in systemic sclerosis | |
Nailfold capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal. | |
Novel autoantibody markers for early and seronegative rheumatoid arthritis | |
Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines | |
Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope | |
Quantification of IFNγ- and IL17-producing cells after stimulation with citrullinated proteins in healthy subjects and RA patients | |
Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. | |
Reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases. | |
Reliability of the quantitative assessment of peripheral blood perfusion by laser speckle contrast analysis in a systemic sclerosis cohort. | |
Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'. | |
Reuma leren begrijpen : inzicht in de vele types reuma, ontstaan en behandelingsvormen, met praktische voorbeelden en adviezen | |
Reumapositief : anders omgaan met een chronische aandoening | |
Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. | |
Rhumatopositif : gérer votre santé avec positivité | |
Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis | |
Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis | |
Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: an extended methodological approach. | |
Specific Antinuclear Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis Are Associated with Improvement of Skin Thickening. | |
Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity | |
Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. | |
Take Five : het leefstijlplan dat werkt om je gezondheid zelf in handen te nemen | |
Take five : le plan de vie incontournable, pour prendre votre santé en main | |
Ten-year followup of infliximab therapy in rheumatoid arthritis patients with severe, longstanding refractory disease: a cohort study | |
Tumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification? | |
Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. | |
Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. | |
Vaccinations in patients with immune-mediated inflammatory diseases | |
Work participation and work transition in patients with systemic sclerosis: a cross-sectional study. |